Skip to main content

Lenz Brian's Form 4 filing

Adma Biologics, Inc. (ADMA) · filed Aug 17, 2023

Accession no.
0001140361-23-040321
Filed
Aug 17, 2023
Trade date
Aug 15-16, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 9 non-derivative transactions and 6 derivative transactions. Open-market sales total $1.77M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lenz BrianCIK 0001283260Officer (EVP, CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2023Common StockSSaleDisposed−211,578$4.60F1−$973,258.8782,013Direct
Aug 15, 2023Common StockMOption exerciseAcquired+97,395$1.67+$162,649.65879,408Direct
Aug 15, 2023Common StockMOption exerciseAcquired+83,979$2.35+$197,350.65963,387Direct
Aug 15, 2023Common StockMOption exerciseAcquired+85,416$2.92+$249,414.721,048,803Direct
Aug 15, 2023Common StockMOption exerciseAcquired+200,000$3.22+$644,0001,248,803Direct
Aug 15, 2023Common StockMOption exerciseAcquired+150,000$3.71+$556,5001,398,803Direct
Aug 15, 2023Common StockMOption exerciseAcquired+192,472$3.66+$704,447.521,591,275Direct
Aug 15, 2023Common StockFTax withholdingDisposed−631,078$4.61−$2,909,269.58960,197Direct
Aug 16, 2023Common StockSSaleDisposed−178,184$4.45F2−$792,918.8782,013Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 15, 2023Common StockMOption exerciseDisposed−97,395$1.67−$162,649.65177,605Direct
Aug 15, 2023Common StockMOption exerciseDisposed−83,979$2.35−$197,350.6555,021Direct
Aug 15, 2023Common StockMOption exerciseDisposed−85,416$2.92−$249,414.7214,584Direct
Aug 15, 2023Common StockMOption exerciseDisposed−200,000$3.22−$644,0000Direct
Aug 15, 2023Common StockMOption exerciseDisposed−150,000$3.71−$556,5000Direct
Aug 15, 2023Common StockMOption exerciseDisposed−192,472$3.66−$704,447.520Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.65, inclusive.

Referenced by the price of 1 transaction in Table I.

F2

Reflects the weighted average price of sales on August 16, 2023. The shares were sold in multiple transactions at prices ranging from $4.40 to $4.535, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)